

# **Pfizer Specialty UK Limited**

**Directors' report and  
financial statements**

**Year ended 30 November 2021**

Registered number: 06801717



# Pfizer Specialty UK Limited

## Directors’ report and financial statements

<i>Contents</i>	<i>Page</i>
Directors and other information	1
Directors’ report	2
Statement of directors’ responsibilities	3
Balance sheet	4
Notes forming part of the financial statements	5 - 6

# Pfizer Specialty UK Limited

## Directors and other information

<b>Directors</b>	DI Highton JA Mount
<b>Registered office</b>	C/o Pfizer Ltd Ramsgate Road Sandwich Kent CT13 9NJ
<b>Registered number</b>	06801717

# Pfizer Specialty UK Limited

## Directors' report

The directors hereby submit their annual report and the financial statements of the company for the year ended 30 November 2021.

### Principal activities and business review

The company is dormant and the directors do not have any current plans to change the company's activities.

### Results and dividends

The financial statements for the year ended 30 November 2021 are set out on pages 4 to 6.

The result for the year was £Nil (2020: £Nil). No dividends were paid or proposed during the period (2020: £Nil).

### Directors and directors' interests

The directors who held office during the year and up to the date of signing these financial statements, unless otherwise noted, were:


IE Franklin (resigned 9 February 2021)  
JA Mount  
DI Highton

At no time during the year did any of the directors have any interest in the shares of the company.

### Auditors

In accordance with Section 480 of the Companies Act 2006, the company has been dormant since the end of the previous financial year. It is therefore exempt from the obligation to appoint auditors as otherwise required by Section 475 of the said Act.

By order of the board

DocuSigned by:  
  
2660F72693E3433...

DI Highton  
Director

Date: May 23, 2022

## Pfizer Specialty UK Limited

### Statement of directors' responsibilities in respect of the Directors' report and the financial statements

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law they have elected to prepare the financial statements in accordance with UK accounting standards and applicable law (UK Generally Accepted Accounting Practice).

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- assess the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- use the going concern basis of accounting unless they either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the company and to prevent and detect fraud and other irregularities.

# Pfizer Specialty UK Limited

## Balance sheet at 30 November 2021

Registered Number: 06801717

	<i>Notes</i>	<b>2021</b> £	2020 £
<b>Current Assets</b>			
Debtors	5	1	1
		<hr/>	<hr/>
<b>Total assets</b>		<b>1</b>	<b>1</b>
		<hr/>	<hr/>
<b>Capital and reserves</b>			
Called up share capital	6	1	1
		<hr/>	<hr/>
<b>Shareholders' funds</b>		<b>1</b>	<b>1</b>
		<hr/>	<hr/>

For the year ended 30 November 2021 the company was entitled to an exemption from the obligation to appoint auditors under Section 480 of the Companies Act 2006.

Members have not required the company to obtain an audit of its financial statements for the year in question in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibility for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These financial statements were approved by the board of directors and were signed on its behalf on 23 May 2022 by:

DocuSigned by:  
  
 2660F72693E3433...  
*DI Highton*  
 Director

# Pfizer Specialty UK Limited

## Notes

*forming part of the financial statements*

### 1. Statement of Accounting Policies

#### **Basis of Preparation**

The financial statements have been prepared in accordance with applicable accounting standards and under the historical cost accounting rules.

Under Financial Reporting Standard 1 (Revised) the company is exempt from the requirement to prepare a cash flow statement on the grounds that a parent undertaking consolidates the company's financial statements in its own published consolidated financial statements.

### 2. Profit and loss account

The company has not traded during the year or prior year and received no income and incurred no expenditure. Consequently, the opening and closing accumulated profit and loss account remains at £Nil. Additionally, the company had no other gains and losses or any cash flows during these periods.

### 3. Remuneration of directors

None of the directors received emoluments or accrued retirements benefit in respect of qualifying services they provided to the company in 2021 (2020: none).

### 4. Staff numbers and costs

The company did not employ any staff during either the current or prior period.

### 5. Debtors

	2021	2020
	£	£
Amounts owed by group undertaking	1	1
	<u>          </u>	<u>          </u>

All amounts fall due within one year.

# Pfizer Specialty UK Limited

## Notes

*forming part of the financial statements (continued)*

### 6. Called up share capital

	2021 £	2020 £
<i>Allotted, called up and fully paid</i>		
1 ordinary share of £1 each	1	1
	<u>1</u>	<u>1</u>

### 7. Related party disclosures

The company is controlled by FoldRx Pharmaceuticals Incorporated. The ultimate controlling company is Pfizer Inc., a company incorporated in the United States of America.

The company has availed of the exemption in FRS 8: *Related Party Disclosures (FRS 8)* from the requirement to disclose details of transactions with wholly owned group undertakings. There were no transactions in the year. Details of the availability of the group consolidated financial statements are given in note 8.

### 8. Ultimate parent company and parent undertaking of larger group of which the company is a member

The company is part of the world-wide group of companies whose ultimate parent is Pfizer Inc., incorporated in the United States of America. The only group in which the results of this company are consolidated is that headed by Pfizer Inc. Copies of the ultimate parent company's financial statements may be obtained from Pfizer Inc., 235 East 42<sup>nd</sup> Street, New York, NY10017 USA.

The immediate holding company is Fold Rx Pharmaceuticals Inc, a company incorporated in the United States of America.